(Street)

(City)

**NEW YORK** 

NY

(State)

10022

(Zip)

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Eychange Act of 1934

												Company			1934	•								
Name and Address of Reporting Person*     ORBIMED ADVISORS LLC				2. Issuer Name <b>and</b> Ticker or Trading Symbol  Kala Pharmaceuticals, Inc. [ KALA ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)												
(Last) (First) (Middle) 601 LEXINGTON AVENUE, 54TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 07/25/2017								Officer (give title X below)  See Remarks											
(Street) NEW YORK NY 100  (City) (State) (Zip)				4. If <i>i</i>	Form filed by More than Person  6. Individual or Joint/Group Filing Line)  Form filed by More than Person								eporting	ting Person										
(City)	(518	·	(Zip)		) Orivo	His ro	S	rition	Λοαιιί	rod	_	Dianasa	4 of	or P	onofi	ioio	Ilv Own							
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Year		2A. De Execut r) if any		ed	3. Transaction Code (Instr. 8)		n	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)				r	5. Amount Securities Beneficial Owned			6. Ownership Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership		
									Code	v	,	Amount		(A) or (D)	Price	.	Reported Transacti	ollowing eported ransaction(s) nstr. 3 and 4)		(Instr. 4)		(Instr. 4)		
Common Stock				07/25/2017				C			2,055,9	46	A	(1)		2,055,946			I		See Footnotes <sup>(3)(4)</sup>			
Common Stock				07/25/2017				P			319,33	33	A	\$15		2,375	2,375,279		I	I So		tes <sup>(3)(4)</sup>		
			Т	able II - D					•	-		posed o				y O	wned							
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	ite Exec		4. Transac Code (I 8)		Deriva Acquir Dispos	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable Expiration Date (Month/Day/Year)		ate	Securities Underly		erlying		8. Price Derival Securit (Instr.	ive d y S i) E	9. Number of derivative Securities Beneficially Owned		10. Ownersh Form: Direct (Dor Indire	ip Indire Benef Owne	Beneficial Ownership	
					Code	v	(A)			e rcisab	ble	Expiration Date	Title		Amount of Number of Shares				Following Reported Transaction(s) (Instr. 4)		(I) (Instr		<del>4</del> )	
Series C Preferred Stock	(1)	07/25/2017			С			10,707,9	985	(2)		(2)		mmon tock	2,05	5,94	6 \$0			0	I	See Footn	otes(3)(4)	
ORBIME (Last)	D ADV	Reporting Person ISORS LL  First) VENUE, 54TH	<u>C</u>	(Middle)			-																	
NEW YORI	K N	NY		10022			_																	
(City)	(:	State)		(Zip)																				
		Reporting Perso																						
(Last) (First) (Mid 601 LEXINGTON AVENUE, 54TH FLOOR				(Middle)																				

1. Name and Address of Reporting Person*  ISALY SAMUEL D									
(Last)	(First)	(Middle)							
601 LEXINGTON AVENUE, 54TH FLOOR									
(Street)									
NEW YORK	NY	10022							
(City)	(State)	(Zip)							

## **Explanation of Responses:**

- 1. The Series C Preferred Stock was converted into Common Stock on a 5.2083-for-one basis.
- 2. The Series C Preferred Stock was convertible into Common Stock at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration
- 3. The reportable securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP VI. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. By virtue of such relationships, GP VI, Advisors and Isaly may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- 4. This report on Form 4 is jointly filed by GP VI, Advisors, and Isaly. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

## Remarks:

In connection with the closing of the Issuer's initial public offering, which occurred on the same day as the transactions reported on this filing, the Reporting Persons will no longer be deemed to beneficially own greater than 10% of the outstanding shares of the Issuer.

> /s/ Samuel D. Isaly 07/27/2017

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.